RNS Number : 4909L
Destiny Pharma PLC
23 April 2018
 

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Posting of Annual Report and Accounts, and Notice of AGM

 

Brighton, United Kingdom - 23 April 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), announces that the annual report and accounts of the Company for the year ended 31 December 2017 ("Annual Report"), and the notice of the Company's Annual General Meeting ("AGM") are now available on the Company's website at www.destinypharma.com

 

The Annual Report will be posted to shareholders today.

 

The AGM is to be held at 10.00am on 31 May 2018 at the offices of FTI Consulting LLP at 200 Aldersgate, London EC1A 4HD.

 

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Simon Sacerdoti, CFO

pressoffice@destinypharma.com  

+44 (0)1273 704 440

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

destinypharma@fticonsulting.com  

+44 (0) 20 3727 1000

 

Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)

Philip Davies / Will Goode, Corporate Finance

Andrew Keith, Healthcare Equity Sales

+44 (0)20 7894 7000

 

finnCap Ltd (Joint Broker)

Geoff Nash /Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

+44 (0)20 7220 0500

 

 

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com  

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCILMMTMBABBAP